DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
This is a Final Office Action.
Claims 1-11, 14, 15, 17-19, 21-25 and 28-30 are pending and under consideration.
Specification
The objection to the abstract of the disclosure is withdrawn based on the amendments..
Claim Objections
The objection to claim 1 because of the phrase, “C1-4 alkyl amino di(C1-4 alkyl)amino” is missing a comma between the two groups, see the definition of R7, is withdrawn based on the amendments.
The objection to claims 12 and 16 because of the phrase, “any one of” is withdrawn based on the amendments.
Claim 1 is objected to because of the following informalities: the phrase, “C1-4 alkyl amino di(C1-4 alkyl)amino” is missing a comma between the two groups, see the definition of Re and Rf, page 4 of 18. Appropriate correction is required.
Claim 1 is objected to because of the following informalities: the formula is blurry and should be replaced. Appropriate correction is required.
Claim 28 is objected to because of the following informalities: the phrase “in need thereof” is needed after the term “person” in said claim.
Claims 21 and 23 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Claim Rejections - 35 USC § 112
The rejection of claim 16 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for the term “trifluoromethyl” is withdrawn based on the amendments.
The rejection of claim 12 under 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for the term “halo” is withdrawn based on the amendments.
The rejection of claims 25-27 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a method of treating pain and pruritus; and a method of decreasing ion flux through a voltage-dependent sodium channel, does not reasonably provide enablement for a method of treating cardiovascular diseases, respiratory diseases, psychiatric diseases or cancer generally, is withdrawn based on the amendments.
The following is a quotation of 35 U.S.C. 112(b):
(B) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1-11, 14, 15, 17-19, 24, 25 and 28-30 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention.
In claim 1, the phrase “methyl or ethyl substituted by phenyl” is ambiguous and vague. Does the claim encompass methyl not substituted with phenyl? Or is methyl and ethyl substituted with phenyl? Any dependent claim that does not address the deficiency is also rejected. Thus, claims 1-11, 14, 15, 17-19, 24, 25 and 28-30 are rejected.
The following is a quotation of the fourth paragraph of 35 U.S.C. 112:
Subject to the [fifth paragraph of 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
Claim 22 is rejected under 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. The term “cyclobutyl” in claim 22 does not further limit and is broader than claim 1, in the definition of R8. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements.
The rejection may be overcome by replacing with F, Cl, Br and I.
The following is a quotation of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), first paragraph:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1-11, 14, 15, 17-19, 24, 25 and 28-30 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
This is a new matter rejection.
The definition of R8 has been amended to include 2,3-dihydro-1H-indenyl and pyridyl. It is noted that there are species with indenyl and pyridyl rings at R8. However, the amended genus is not supported by the disclosure. Thus, claims 1-11, 14, 15, 17-19, 24, 25 and 28-30are rejected.
Claim Rejections - 35 USC § 102
The rejection of claims 1, 2, 12 and 24-28 under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Brand et al. (US 20110312921), is withdrawn based on the amendments.
The rejection of claims 1-3, 5-8, 10, 12, 13, 18 and 24 under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Wilson et al. (US 20110082117), is withdrawn based on the amendments.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSANNA MOORE whose telephone number is (571)272-9046. The examiner can normally be reached Monday - Friday, 10:00 am to 7:00 pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached on 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SUSANNA MOORE/Primary Examiner, Art Unit 1624